gMendel receives grant from the Innovation Fund Denmark.
27 May, 2022, Copenhagen – gMendel announces that the Innovation Fund Denmark has invested 200,000 Euro in gMendel’s novel diagnostic technology. The grant will enable us to further develop our technology for the detection of the most common aneuploidies, microdeletion syndromes and the 3 diseases that comprise the Basic Carrier Testing for all ethnicities (Fragile X, Cystic Fibrosis, Spinal Muscular Atrophy).
There are 350 million people worldwide, half of them children, who suffer from rare diseases/genetic disorders. Currently, diagnosis of genetic disorders relies on a set of non-accurate conventional techniques, built on costly and complex advanced genomic technologies. Low accuracy of the conventional techniques is a challenge, which impacts the willingness of the National Health Systems (NHS) and Health Care Professionals (HCPs) to include them timely in their routine practice. Although Basic Carrier Testing (BCT), Non-Invasive Prenatal Testing (NIPT) and Newborn Screening (NBS) programmes exist in many countries, they are not harmonized. This leads to significant disparity and discrepancies, both in terms of the access to screening and the number of genetic disorders screened (ranging from 2 to 30). As a result, even after dozens of medical examinations, which take on average 7 years and €2.5 million lifetime costs, 40% of patients are still misdiagnosed, creating a heavy human, economic and societal burden.
gMendel is working to eliminate financial, social and regulatory barriers and include its gMendel®Test diagnostic technology in as many national screening programmes as possible. We aim to revolutionize the BCT, NIPT and NBS in Europe and around the world, by introducing a harmonized screening panel that uses accurate genomic technology, AI/machine learning and blockchain. Our mission is to offer a real-time, reliable testing that can be made available widely at a low cost, ensuring the highest security & patient data encryption.
Dr. Chris Kyriakidis, CEO and co-founder of gMendel, commented: “We are very pleased to have received this grant from the Innovation Fund Denmark, which will allow us to further develop our novel In-Vitro Diagnostic (IVD) technology and expand its efficacy to more genetic disorders, leveraging on the full potential of our Phivea® platform.”
About the Innovation Fund Denmark
The Innovation Fund Denmark invests in entrepreneurs, researchers and businesses that create value for Denmark and new solutions to society’s biggest challenges. The organization funds risk-high potential projects with areas of interest in a more effective health care, cleaner environment, climate mitigating solutions, healthier food, green transport, start-up journeys – and many more. Its mission is to strengthen and foster strategic research and innovation projects in all of Denmark.
27 May 2022gMendel announces that the Innovation Fund Denmark has invested 200,000 Euro in gMendel's novel diagnostic technology.
11 May 2022Denmark’s vision to become a front-runner in the use of artificial intelligence reflects on the country’s national strategy for AI.
06 May 2022gMendel® announces CE marking for its Phivea® v1.0.0 platform, a novel screening technology for the detection of Klinefelter Syndrome.
26 Apr 2022Recent systematic review determines the prevalence of Klinefelter syndrome amongst transgender individuals presumed male at birth.